Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Female Genital Diseases Clear all
Active, not recruiting Phase 1Phase 2 Interventional

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT05864144
View directory record Official record
Conditions
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
SNS-101 (anti-VISTA), Cemiplimab
Drug
Lead sponsor
Sensei Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

NCT01163552
View directory record Official record
Conditions
Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
Interventions
Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jul 23, 2026, 10:12 PM EDT
Completed No phase listed Observational

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

NCT00499187
View directory record Official record
Conditions
HIV Infections, Fanconi Syndrome, Kidney Disease, Renal Impairment
Interventions
Blood Draws
Procedure
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 4 Interventional

Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women

NCT00628771
View directory record Official record
Conditions
Pregnancy, HIV Infections, Sexually Transmitted Diseases
Interventions
CenteringPregnancy Plus (CP+), Usual care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
1,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 23, 2026, 10:12 PM EDT
Suspended Not applicable Interventional

ORCHID: An Online Intervention for Persons With HIV (Miami)

NCT05935644
View directory record Official record
Conditions
HIV/AIDS, HPV Infection
Interventions
ORCHID
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT02046421
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mifepristone, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 23, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

NCT07050771
View directory record Official record
Conditions
Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer
Interventions
Comprehensive multimodal prehabilitation (CMMP)
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

NCT02469116
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Docetaxel, Carboplatin, Pegylated G-CSF
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Not applicable Interventional

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

NCT00004936
View directory record Official record
Conditions
Cervical Cancer
Interventions
iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine
Drug · Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Morristown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer

NCT00287911
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, topotecan hydrochloride, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT00883116
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Ixabepilone, Doxorubicin, Paclitaxel
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Mobile, Alabama • Englewood, Colorado • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00066729
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
NY-ESO-1 peptide vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

NCT02875119
View directory record Official record
Conditions
HIV Infection
Interventions
Griffithsin Gel, Placebo Gel
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jul 23, 2026, 10:12 PM EDT
Completed No phase listed Observational

Characteristics of Women With Reproductive Concerns

NCT02429336
View directory record Official record
Conditions
Endocrine Disorders of Female Reproductive System
Interventions
Not listed
Lead sponsor
University of Tennessee
Other
Eligibility
8 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

NCT02472184
View directory record Official record
Conditions
Uterine Fibroids, Vaginal Bleeding
Interventions
Office hysteroscopy, Endometrial biopsy
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jul 23, 2026, 10:12 PM EDT
Completed No phase listed Observational

Tissue Samples and Bodily Fluid Specimens Banking

NCT02431884
View directory record Official record
Conditions
Endocrine Disorders of Female Reproductive System
Interventions
collect body fluids/tissues & med history
Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
8 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

NCT01788215
View directory record Official record
Conditions
Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions
doxycycline, Sugar Pill
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vietnamese Women's Health Project III

NCT01704235
View directory record Official record
Conditions
Cervical Cancer
Interventions
Demographic Form and Semi-Structured Interview Guide
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Jul 23, 2026, 10:12 PM EDT